Ascentage Pharma Group International American Depository Shares (AAPG) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, gaining 46.5% versus a loss of 63.8%. Tyra Biosciences is the larger company by market cap ($1.41 billion vs $1.38 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | TYRA |
|---|---|---|
| Share price | $14.80 | $20.53 |
| Market cap | $1.38B | $1.41B |
| 1-day change | +1.73% | +2.78% |
| YTD return | -44.55% | -24.04% |
| 1-year return | -63.83% | +46.52% |
| 5-year return | — | +22.22% |
| EPS (TTM) | $-2.26 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.50 | $40.65 |
| 52-week low | $14.46 | $13.29 |
| Distance from 52-week high | -60.53% | -49.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.42% | +131.18% |
| Average volume | 6.37K | 859.95K |
| Shares outstanding | 93.39M | 68.76M |
| Employees | 828 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed AAPG by 110.3 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
AAPG vs TYRA FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.41B compared with $1.38B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or TYRA?
TYRA returned +46.52% over the past 12 months, compared with -63.83% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.